HighTower Advisors’s Pfizer PFE Stock Holding History

HighTower Advisors’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-90,000	Closed	-$78K	–	3970
2024 Q4	$78K	Buy	+90,000	New	+$2.44M	﹤0.01%	3413
2024 Q3	–	Sell	-2,800	Closed	-$58	–	3911
2024 Q2	$58	Buy	+2,800	New	+$77.1K	﹤0.01%	3645
2024 Q1	–	Sell	-1,000	Closed	-$2.81K	–	3907
2023 Q4	$2.81K	Buy	1,000 +960	+2,400%	+$29K	﹤0.01%	3497
2023 Q3	$2.92K	Buy	+40	New	+$1.42K	﹤0.01%	3452
2023 Q2	–	Sell	-5,100	Closed	-$4.08K	–	3623
2023 Q1	$4.08K	Buy	5,100 +5,005	+5,268%	+$216K	﹤0.01%	3246
2022 Q4	$3.65K	Buy	95 +10	+12%	+$479	﹤0.01%	3237
2022 Q3	$19K	Sell	85 -8,015	-99%	-$389K	﹤0.01%	2977
2022 Q2	$12K	Buy	8,100 +8,019	+9,900%	+$409K	﹤0.01%	3049
2022 Q1	$14K	Buy	81 +49	+153%	+$2.54K	﹤0.01%	3195
2021 Q4	$78K	Sell	32 -31,868	-100%	-$1.58M	﹤0.01%	2967
2021 Q3	$11K	Buy	+31,900	New	+$1.41M	﹤0.01%	3034
2021 Q2	–	Sell	-100	Closed	-$9K	–	3329
2021 Q1	$9K	Buy	100 +60	+150%	+$2.13K	﹤0.01%	2935
2020 Q4	$1K	Buy	+40	New	+$1.47K	﹤0.01%	2583
2016 Q1	–	Sell	-104,451	Closed	-$4K	–	2170
2015 Q4	$4K	Buy	+104,451	New	+$3.29M	﹤0.01%	2012

Other funds holding PFE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

HighTower Advisors's PFE Position: Q2 2026 in Review

HighTower Advisors reduced its Pfizer (PFE) stake by 1.2% in Q2 2026, selling an estimated $854K and leaving 2,615,514 shares worth $63M. The position accounts for 0.06% of the portfolio, ranked #315.

HighTower Advisors first reported a position in PFE in Q2 2013 and has held it in 53 quarters since. The position peaked at $236M in Q4 2021. 2,827 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

HighTower Advisors held 2,615,514 shares of Pfizer worth $63M as of Q2 2026.
HighTower Advisors sold 32,629 Pfizer shares in Q2 2026, an estimated $854K.
Pfizer made up 0.06% of HighTower Advisors's portfolio in Q2 2026, its #315 holding.
HighTower Advisors first reported a position in Pfizer in Q2 2013 and has held it in 53 quarters since.
HighTower Advisors's Pfizer position peaked at $236M in Q4 2021.
2,827 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on HighTower Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.